



Characterization of antioxidant fraction of *Trapa japonica* pericarp and its hepatic protective effects *in vitro* and *in vivo*

Journal:	<i>Food & Function</i>
Manuscript ID	FO-ART-11-2015-001405.R1
Article Type:	Paper
Date Submitted by the Author:	03-Feb-2016
Complete List of Authors:	<p>Kim, Yon-Suk; Konkuk University, Department of Biotechnology Kim, Eun-Kyung; Konkuk University, Biotechnology Hwang, Jin-Woo; Konkuk University, Department of Biotechnology Seo, Il-Bok; Semyung University, Department of Anatomy, College of Oriental Medicine Jang, Jae-Hyuk; Korea Research Institute of Bioscience and Biotechnology, Chemical Biology Research Center Son, Sangkeun; Korea Research Institute of Bioscience and Biotechnology, Chemical Biology Research Center Jeong, Jae-Hyun; Korea National University of Transportation, Department of Food Science and Technology Moon, Sang-Ho; Konkuk University, Nokyong Research Center Jeon, Byong-Tae ; Konkuk University, Nokyong Research Center Park, P.-J.; Konkuk University, Biotechnology</p>

**Characterization of antioxidant fraction of *Trapa japonica*
pericarp and its hepatic protective effects *in vitro* and *in vivo***

Yon-Suk Kim^a, Eun-Kyung Kim^{a,c}, Jin-Woo Hwang^a, Il-Bok Seo^b, Jae-Hyuk Jang^c,
Sangkeun Son^c, Jae-Hyun Jeong^d, Sang-Ho Moon^e, Byong-Tae Jeon^e, Pyo-Jam Park^{a,e*}

^aDepartment of Biotechnology, Konkuk University, Chungju, 380-701, Korea

^bDepartment of Anatomy, College of Oriental Medicine, Semyung University, Jecheon,
390-711, Korea

^cChemical Biology Research Center, Korea Research Institute of Bioscience and
Biotechnology, Ochang, 363-883, Korea

^dDepartment of Food Science and Technology, Korea National University of Transportation,
Chungju, 380-702, Korea

^eNokyong Research Center, Konkuk University, Chungju, 380-701, Korea

*Corresponding author; Park, P. J., Tel: +82-43-840-3588; Fax: +82-43-852-3616; E-mail
address: parkpj@kku.ac.kr

1 **Abstract**

2 Ethanolic extract of *Trapa japonica* pericarp (TJP) and its various fractions were evaluated for
3 their antioxidant potential. The ethyl acetate fraction (EF) from TJP exhibited significant
4 antioxidant and protective effects against *tert*-butylhydroperoxide (*t*-BHP)-induced oxidative
5 damage *in vitro* and *in vivo*. *In vitro* experimental results showed that the EF suppressed *t*-BHP-
6 induced damage in Chang cells by inhibiting reactive oxygen species generation and regulating
7 the mitochondrial membrane potential. Furthermore, western blot analysis showed that the EF
8 effectively inhibited *t*-BHP-induced apoptosis by suppressing caspase-3, caspase-7, caspase-8,
9 and caspase-9. *In vivo* study, the EF significantly prevented serum increases in glutamate
10 oxaloacetate transaminase and glutamate pyruvate transaminase and hepatic malondialdehyde
11 levels caused by *t*-BHP. Furthermore, the EF markedly increased hepatic superoxide dismutase,
12 catalase, and glutathione levels. Histopathological examinations further confirmed that the EF
13 could protect the liver from *t*-BHP-induced oxidative injury. These findings indicate that the EF
14 could be developed as a therapy or to prevent hepatic injury.

15

16 **Keywords :** *Trapa japonica*, *tert*-butylhydroperoxide, 3,9-dihydroxy-dibenzo[b,d]pyran-6-one,
17 reactive oxygen species

18

19 **Introduction**

20 Oxidative stress is defined as an imbalance between antioxidants and free radicals, which can
21 potentially lead to cellular damage.¹ Oxidative stress is induced by reactive oxygen species
22 (ROS), such as superoxide anions ($O_2^{\cdot-}$), hydrogen peroxide (H_2O_2), and hydroxyl radicals
23 ($\cdot OH$).²⁻³ Cellular ROS play important roles in regulating various physiological functions, and
24 they represent an essential part of aerobic metabolism.⁴ Excessive ROS generation disrupts the
25 cellular antioxidant defense system and may lead to oxidative stress.⁵ It has been reported that
26 the deleterious effects of ROS on human cells may result in oxidative stress-induced
27 programmed cell death or apoptosis.⁶ Antioxidants are capable of preventing oxidative damage.
28 Natural antioxidants have been widely used as replacements for conventional synthetic
29 antioxidants in food and food supplements because natural products are considered safer and
30 effective.⁷

31 In Asia, the fruit of *T. japonica* has been eaten by steaming and boiling. The pericarp of *T.*
32 *japonica* is considered to be the waste and generally discarded. However, the husk of water
33 chestnut contains many dietary fibers⁸ and phenolic compounds such as eugenin, 1,2,3,6-tetra-
34 O-galloyl-beta-D-glucopyranose (TGG), trapain, ellagic acid, eugenin and gallic acid.⁹⁻¹⁰ *tert*-
35 Butylhydroperoxide (*t*-BHP)-induced oxidative stress and hepatotoxicity are associated with an
36 imbalance in the oxidant/antioxidant system of the liver.¹¹⁻¹²

37 The aim of the present study was to investigate the hepatoprotective and antioxidant activities of
38 *Trapa japonica* pericarp-derived fractions against *t*-BHP-induced oxidative damage *in vitro* and
39 *in vivo*. To confirm *t*-BHP-induced apoptosis and to study the anti-apoptotic effect of the ethyl
40 acetate fraction (EF) of *T. japonica* pericarp, we performed immunoblot analyses of Bax, Bcl-2,
41 caspase-3, caspase-7, caspase-8, and caspase-9. Additionally, we confirmed the protective effect
42 of the EF on lipid peroxidation, glutathione content, and antioxidant enzymes in male
43 imprinting control region (ICR) mice that have sustained *t*-BHP-induced acute oxidative
44 damage.

45

46 **Materials and Methods**

47 **Materials**

48 Dulbecco's Modified Eagle's medium (DMEM), fetal bovine serum (FBS), and penicillin-
49 streptomycin were purchased from Hyclone (Logan, Utah, USA). *N*-Acetyl-L-cysteine (NAC),
50 silymarin, *t*-BHP, 2',7-dichlorodihydrofluorescein diacetate (DCFH-DA), 3-(4, 5-
51 dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT), propidium iodide (PI), and
52 rhodamine 123 were purchased from Sigma Chemical Co. (St. Louis, MO, USA). Hoechst
53 33342 was purchased from Invitrogen. All other reagents were of the highest grade available
54 commercially. Dried *T. japonica* was obtained from Jecheon herbal medicine mall (Jecheon,

55 Korea) in January 2014. The sample was authenticated by Prof. K.H. Leem (Department of
56 Herbology, Semyung University) and voucher specimen (KUB13-20) was deposited in the
57 Konkuk University Herbarium. The pericarp collected from *T. japonica* was ground into a fine
58 powder for ease of extraction.

59

60 **Preparation of *T. japonica* pericarp fractionation**

61 Ethanol extraction of the dried *T. japonica* pericarp (TJP; 6 kg) was carried out in duplicate
62 using 70% ethanol under reflux for 1 day. The total filtrate was concentrated under reduced
63 pressure to produce the ethanolic extract (257.9 g, 4.29% yield). Ethanolic extract (100 g) was
64 suspended in water and partitioned with hexane (2 L, thrice), chloroform (2 L, thrice), ethyl
65 acetate (2 L, thrice), *n*-butanol (2 L, thrice), and residual aqueous fraction successively, to
66 remove solvent and produce hexane (HF, 4.117 g, 4.11% yield), chloroform (CF, 2.146 g, 2.14%
67 yield), ethyl acetate (EF, 49.653 g, 49.65% yield), *n*-butanol (BF, 19.95 g, 19.95% yield), and
68 aqueous (AF, 9.685 g, 9.68% yield) fractions. Each fraction was collected, dried, and stored at
69 4°C.

70

71 **Isolation and characterization of compounds from EF**

72 The Inspire C18 column (250 mm × 21.2 mm, 10 μm) was operated in the HPLC (ultimate 3000,

73 Thermo Scientific) system using an injection volume of 1.0 mL at a flow rate of 5 mL/min and a
74 detection wavelength of 254 nm. The mobile phases were 0.1% acetic acid in water (A) and
75 methanol (B), and the gradient condition were 0-55 min, 0-100 B%, and 55-60 min, 100 B%.

76 We isolated 4 fractions (labeled as EF1-EF4) from the EF according to their respective peaks.

77 Liquid chromatography-mass spectrometry (LC-MS) was performed using an LTQ XL linear
78 ion trap (Thermo Scientific, USA) equipped with an electrospray ionization (ESI) source that
79 was coupled to a rapid separation LC (RSLC; ultimate 3000, Thermo Scientific) system (ESI-
80 LC-MS) using an HSS T3 column (Waters, UK) (2.1 × 150 mm; 2.5 µm particle size). The
81 linear gradient of the binary solvent system consisted of solvent A (water with 0.1% formic acid)
82 and solvent B (acetonitrile) at a flow rate of 0.3 mL/min. A linear gradient was initiated with 5%
83 B and linearly increased to 100% at 0-15 min. The ESI (negative ion) parameters for the EF4
84 were: source voltage (+5 kV), entrance capillary voltage (+18 V), entrance capillary temperature
85 (275°C), and tube lens voltage (+120 V). The scan range was fixed from m/z 50 to 1500. The
86 data-dependent mass spectrometry experiments were controlled using the menu driven software
87 provided with the Xcalibur system (version 2.2 SP1.48; Thermo Scientific).

88

89 *In vitro* study

90 **DPPH radical scavenging activity**

91 The DPPH radical scavenging activity was measured using an ESR spectrometer (JES-FA
92 machine; JOEL, Tokyo, Japan) according to the technique described by Kim et al.¹³ Sixty
93 microliters of each sample (or ethanol itself as control) was added to 60 μ L of DPPH (60 μ M) in
94 ethanol. After 10 s of vigorous mixing, the solutions were transferred to Teflon capillary tubes
95 and fitted into the cavity of the ESR spectrometer. The spin adducts were determined by the
96 ESR spectrometer exactly 2 min later under the following measurement conditions: central field
97 3475 G, modulation frequency 100 kHz, modulation amplitude 2G, microwave power 5 mW,
98 gain 6.3×10^5 , and temperature 298 K.

99

100 **ABTS radical scavenging activity**

101 For ABTS assay, the procedure followed the method of Erkan et al.¹⁴ with some modifications.
102 The stock solutions included 7.4 mM ABTS cation solution and 2.6 mM potassium persulfate
103 solution. The working solution was then prepared by mixing the two stock solutions in equal
104 quantities and allowing them to react for 14 h at R.T in the dark. The mixture was diluted that its
105 absorbance was adjusted to 1.5 ± 0.02 at 734 nm. To determine the scavenging activity, 0.9 mL
106 of ABTS cation solution was mixed with 0.1 mL of extracts and the absorbance was measured at
107 734 nm after 6 min of reaction at R.T, using ethanol as a control. The antioxidant activities of
108 samples were expressed by Trolox equivalents antioxidant capacity (TEAC), as mM Trolox

109 eq./mg extract.

110

111 **Ferric reducing antioxidant power (FRAP) assay**

112 FRAP assay was carried out by the method of Benzie and Strain¹⁵ with minor modification. The

113 method is based on the reduction of a ferric 2,4,6-tripyridyl-s-triazine complex (Fe^{3+} -TPTZ) to

114 the ferrous form (Fe^{2+} -TPTZ). To conduct the assay, a 3 mL aliquot of a FRAP reagent, a

115 mixture of 0.3 M acetate buffer, 10 mM TPTZ in 40 mM HCl, and 20 mM ferric chloride

116 (10:1:1 v/v/v), were combined with 1 mL of samples. To determine the antioxidant capacity of

117 the samples, the absorbance values were compared with those obtained from the standard curves

118 of FeSO_4 (0-5 mM). The antioxidant capacity values were expressed as mM FeSO_4 equivalents

119 in mg extract (mM FeSO_4 eq./mg extract).

120

121 **Cell culture**

122 Chang liver cells purchased from American Type Culture Collection (ATCC CCL-13TM) were cultured at

123 37°C in humidified 5% CO_2 , 95% air mixture in DMEM supplemented with heat-inactivated 10%

124 FBS, 100 U/mL penicillin, and 100 $\mu\text{g}/\text{mL}$ streptomycin. Adherent cells were detached by trypsin-

125 ethylenediaminetetracetic acid (EDTA) and plated onto 6-, 48-, or 96-well plates at 70-80% confluence.

126

127 **MTT assay**

128 The cell viability was estimated by MTT assay. Chang liver cells were seeded in 48-well plates
129 at a concentration of 7.0×10^3 cells/well. After 20 h, the cells were treated with various
130 concentrations of samples and incubated in a humidified incubator at 37°C for 1 h. Then, *t*-BHP
131 was added to a final concentration of 100 μ M and incubated for 24 h. Thereafter, 100 μ L of
132 MTT stock solution (0.5 mg/mL) was added and incubated for 4 h. Then, the supernatants were
133 aspirated, and the formazan crystals in each well were dissolved in 150 μ L of dimethyl
134 sulfoxide (DMSO). Absorbance was measured by microplate reader (SpectraMax M2/M2e,
135 Molecular Devices, Sunnyvale, CA, USA) at a wavelength of 540 nm. Relative cell viability
136 was determined by the amount of MTT converted to the insoluble formazan salt. The optical
137 density of the formazan formed in the control cells was considered as 100% viability.

138

139 **Lactate dehydrogenase (LDH) release assay**

140 The activity of LDH released into the culture medium through damaged membranes was
141 measured using the LDH cytotoxicity assay kit (BioVision, CA, USA). Briefly, Chang liver
142 cells were seeded in 96-well plates at a density of 4.0×10^3 cells/well. After 20 h, the cells were
143 treated with various concentrations of the EF and incubated in a humidified incubator at 37°C
144 for 1 h. Then, *t*-BHP was added to a final concentration of 100 μ M and incubated for 24 h. After

145 incubation, 10 μ L of supernatant was added to 100 μ L of LDH reaction mix and incubated for
146 30 min. Absorbance was measured at 450 nm using a microplate reader.

147

148 **Cell cycle analysis by flow cytometry**

149 Cells were plated in 6-well plates (2×10^4 cells/well) with 2 mL of culture medium for 24 h.

150 They were pretreated with the EF for 1 h before exposure to 100 μ M *t*-BHP for 24 h. For flow
151 cytometry cell cycle analysis, cells were harvested and washed twice with PBS buffer (pH 7.4).

152 After fixing in 80% ethanol overnight, cells were washed twice and resuspended in PBS buffer

153 containing 50 μ g/mL PI and 5 μ g/mL ribonuclease A for DNA staining. Cells were then

154 analyzed by flow cytometry (FACSCalibur, Becton & Dickinson Co., Franklin Lakes, NJ, USA).

155 At least 10,000 events were evaluated.

156

157 **Reactive oxygen species (ROS) measurement**

158 Intracellular formation of ROS was assessed as described previously using the oxidation

159 sensitive dye DCFH-DA.¹⁶ Chang liver cells were seeded in 6-well plates (2.0×10^4 cells/well).

160 Cells were pretreated with the EF and incubated for 1 h, followed by 100 μ M *t*-BHP treatment

161 for 24 h. Next, cells were incubated with DCFH-DA (5 μ g/mL) for 30 min at 37 $^{\circ}$ C in the dark.

162 Non-fluorescent cell permeable DCFH-DA dye freely penetrates into cells and is hydrolyzed by

163 intracellular esterase to 2',7-dichlorofluorescein (DCFH), which is trapped inside the cell. The
164 formation of 2',7-dichlorofluorescein (DCF) due to the oxidation of DCFH in the presence of
165 ROS was analyzed by flow cytometry.

166

167 **Measurement of mitochondrial membrane potential (MMP)**

168 Mitochondrial membrane potential was monitored by the fluorescent dye rhodamine 123, which
169 is a cell permeable cationic dye that preferentially enters the mitochondria with highly negative
170 membrane potentials.¹⁷ Depolarization of MMP results in the loss of rhodamine 123 from the
171 mitochondria and a decrease in the intracellular fluorescence intensity. After 24 h treatment with
172 *t*-BHP and pretreatment with the EF for 1 h, rhodamine 123 (10 μ M) was added for 30 min at
173 37°C in the dark. Cells were harvested, washed with PBS, and the MMP was measured by flow
174 cytometry.

175

176 **Apoptosis assay**

177 Cell apoptosis was measured by Annexin V/PI staining. Briefly, after treatment, cells were
178 washed twice with PBS and incubated in 100 μ L of binding buffer containing 5 μ L of Annexin
179 V-FITC and 5 μ L of PI in the dark for 15 min at room temperature. The stained samples were
180 added to 400 μ L of binding buffer and then analyzed by a FACSCalibur flow cytometer and

181 quantified using Cell Quest software.

182

183 **Western blot analysis**

184 Total cell extracts were prepared using PRO-PREP protein extraction solution (iNtRON
185 Biotechnology). Briefly, after treatment with the various concentrations of the EF, cells were
186 harvested, washed once with PBS, and gently lysed for 30 min in 100 μ L of ice-cold PRO-PREP
187 lysis buffer. Lysates were centrifuged at 13,000 \times g at 4°C for 10 min. Supernatants were
188 collected, and protein concentrations were determined using a Bio-Rad protein assay kit (Bio-
189 Rad, Hercules, CA). Samples were stored at -80°C unless immediately used for western blot
190 analysis. Proteins were separated on a sodium dodecyl sulfate (SDS)-polyacrylamide gel,
191 transferred onto polyvinylidene fluoride membranes (PVDF), blocked with 5% skim milk, and
192 incubated at 4°C overnight with primary antibodies. Membranes were washed and incubated
193 with horseradish peroxidase-conjugated secondary antibodies. Chemiluminescence was detected
194 using western ECL substrate, and membranes were subjected to direct densitometry analysis.
195 Images were captured using a charge-coupled device camera system (LAS-3000; Fujifilm,
196 Tokyo, Japan). Band intensity was normalized with respect to β -actin levels as an internal
197 control.

198

199 ***In vivo* study**200 **Animals**

201 Male, 6-week-old ICR mice were purchased from OrientBio Co. (Sungnam, Korea) and were
202 housed with free access to a standard rodent diet (Samyang Feed Co., Ltd., Incheon, Korea) and
203 tap water. Mice were housed in humidity- ($55 \pm 5\%$) and temperature-controlled ($23 \pm 1^\circ\text{C}$)
204 rooms with a 12-h/12-h light/dark cycle for at least 1 week before experimentation. The license
205 number for using experimental animals was KU14102. All animal care and studies were
206 approved by the Institutional Animal Care and Use Committee of Konkuk University in
207 accordance with the principles and guidelines of the U.S. National Institutes of Health Guide for
208 the Care and Use of Laboratory Animals.

209

210 ***t*-BHP-induced oxidative toxicity**

211 The mice were divided into five groups ($n=5$). Group I was the control, and they received oral
212 doses of vehicle for 5 days. Group II was the toxic group, which received oral doses of vehicle
213 for 5 days. Group III received the EF at 50 mg/kg for 5 days, Group IV received the EF at 100
214 mg/kg for 5 days, and Group V received silymarin at 100 mg/kg for 5 days. On the fifth day, all
215 the animal groups except Group I were injected with 2 mmol/kg *t*-BHP intraperitoneally, and 18
216 h later, the mice were euthanized. Blood samples were collected from the heart for the glutamate

217 oxaloacetate transaminase (GOT) and glutamate pyruvate transaminase (GPT) assays. After
218 blood collection, the livers were removed, rinsed with PBS, and stored at -80 °C for biochemical
219 analysis.

220

221 **Preparation of liver homogenates**

222 Following euthanasia, the liver of each mouse was removed and frozen immediately in dry ice.
223 The frozen tissues were stored at -80 °C until further use. Liver homogenates were prepared
224 with 50 mM cold potassium phosphate buffer (pH 7.4). The resulting suspension was
225 centrifuged at 12,000 ×g for 15 min, and the supernatant was collected for further analysis. The
226 cell-free supernatant was used to measure enzyme activity and lipid peroxidation.

227

228 **Determination of antioxidant enzyme activity and lipid peroxidation levels**

229 The activity of superoxide dismutase (SOD), catalase (CAT), and glutathione (GSH) was
230 determined using commercial reagent kits obtained from Cayman Chemical Company (Ann
231 Arbor, MI, USA), according to the instruction manuals. Malondialdehyde (MDA), an end
232 product of lipid peroxidation, was estimated in liver homogenates. The assay involves a reaction
233 between MDA and thiobarbituric acid (TBA), which produces a pink colored MDA-TBA
234 complex.¹⁸ Sample (100 µL) and 200 µL of 1.0 M phosphoric acid were incubated for 15 min on

235 ice. After centrifugation, 200 μ L of supernatant and 200 μ L of 0.67% TBA standard solution
236 were mixed. The tubes were kept on a boiling water bath for 10 min and then cooled under tap
237 water. Supernatant absorbance was read at 532 nm. The standard used for plotting the
238 calibration curve was 1,1,3,3-tetramethoxypropane. The results were expressed as nmol/mg
239 protein.

240

241 **Trolox equivalent antioxidant capacity (TEAC) assay**

242 Seven millimolar 2,2'-azinobis-(3-ethyl-benzothiazoline-6-sulfonate) (ABTS) was reacted with
243 2.45 mM potassium persulfate solution overnight in the dark to generate ABTS cation radical.
244 Later, ABTS cation solution was diluted with ethanol to an absorbance of 0.7 ± 0.05 at 734 nm.
245 Serum (20 μ L) was mixed with 1.0 mL of diluted ABTS cation solution. Absorbance was
246 measured 6 min after the initial mixing at 734 nm. TEAC was expressed as μ M Trolox
247 equivalent/mg protein.

248

249 **Statistical analysis**

250 Data were assessed in triplicate and reported as mean \pm standard deviation. Analysis of variance
251 (ANOVA) and the Dunnett's test (GraphPad Prism 5) were used to identify significant
252 differences between samples ($p < 0.05$).

253

254 **Results**

255 **DPPH radical scavenging activity**

256 The TJP extract and its fractions elicited high DPPH radical scavenging activity. IC₅₀ values of
257 DPPH radical scavenging activity of EE and its fractions (HF, CF, EF, BF, AF) were 1.69 ±
258 0.01, 3.62 ± 0.02, 25.85 ± 0.25, 1.21 ± 0.01 0.01, 1.07 ± 0.01 and 3.28 ± 0.21 µg/mL,
259 respectively (Table 2). Especially, the ethanolic extract and its ethyl acetate and *n*-butanol
260 fraction demonstrated significant DPPH radical scavenging activity compared to the positive
261 control; vitamin C (IC₅₀, 3.11 ± 0.20 µg/mL).

262

263 **ABTS radical scavenging activity**

264 The antioxidant activity in TJP extract and its fractions were determined as Trolox equivalents
265 using the ABTS assay. TJP extract and its fractions were observed to have significant
266 antioxidant action. As depicted in Table 2, the TEAC value of the EF and BF exhibited a similar
267 TEAC value (1.523 ± 0.001, 1.525 ± 0.002 mM Trolox eq./mg extract) as compared to that of
268 vitamin C (1.528 ± 0.001 mM Trolox eq./mg extract).

269

270 **FRAP (ferric reducing antioxidant power) assay**

271 The FRAP assay has been commonly used for rapid evaluation of the total antioxidant capacity
272 of various potential antioxidants. The ferric reducing antioxidant power of TJP extract and its
273 fraction is shown in Table 2. The results displayed that EE (6.439 ± 0.200 mM FeSO₄ eq./mg
274 extract), EF (6.465 ± 0.173 mM FeSO₄ eq./mg extract) and BF (6.512 ± 0.207 mM FeSO₄
275 eq./mg extract) have a similar FRAP antioxidant activity as compared to vitamin C ($6.779 \pm$
276 0.191 mM FeSO₄ eq./mg extract) used as a positive control. These values suggest that the
277 ethanolic extract of TJP, fraction of ethyl acetate and *n*-butanol had a strong ferric reducing
278 antioxidant power.

279

280 **Cell viability**

281 The cytotoxic and protective effects of the TJP ethanolic extract and its fractions on *t*-BHP-
282 induced oxidative stress in Chang cells were determined by MTT and LDH assays. In the MTT
283 assay, cell viability increased following pretreatment with the ethanolic extract of TJP as well as
284 its fractions, including HF, CF, EF, BF, and AF at 20 µg/mL, compared to cells treated with *t*-
285 BHP alone [$50.15 \pm 6.85\%$ cell viability; Figure 2(A)]. The cell viability of the ethanolic
286 extracts from TJP and its fractions HF, CF, EF, BF, and AF in the presence of *t*-BHP was $73.56 \pm$
287 1.54% , $72.24 \pm 0.88\%$, $46.12 \pm 6.03\%$, $75.73 \pm 0.93\%$, $65.81 \pm 2.55\%$, and $52.24 \pm 3.67\%$,
288 respectively. From the experiment dealing with antioxidant activity, it was evident that BF

289 demonstrated highest activity than other fractions and was then followed by EF for antioxidant
290 activity. However, for further experiments, EF was chosen over BF since the former had higher
291 protective effect. As shown in Figure 2(B), pretreatment with the EF dose-dependently
292 alleviated the *t*-BHP-induced reduction in cell viability. The EF showed a stronger protective
293 effect than the positive control, silymarin. Furthermore, *t*-BHP-treatment significantly increased
294 LDH release (3.8 ± 0.1 -fold) into the culture medium, whereas the EF pretreatment (5-20
295 $\mu\text{g/mL}$) significantly diminished this release in a dose-dependent manner Figure 2(C). These
296 results clearly indicate that the EF confers a significant protective effect against *t*-BHP in Chang
297 cells.

298

299 **Identification of active compounds from EF**

300 Isolated EF was analyzed by LC-MS. A total of 16 different organic compounds were identified
301 in the EF based on LC retention time. The 16 chemical constituents (Table 1, Figure 1) are as
302 follows: gallic acid, digalloyl-glucoside, trigalloyl-glucoside, eugenin, tetrahalloyl-glucoside,
303 and ellagic acid. In this study, five digalloyl-glucose and seven trigalloyl-glucoside were
304 detected in the EF from TJP. From the EF (100 mg), along with 16 known compounds, we have
305 discovered another bioactive ingredient by repeated column chromatography. We have named
306 this as compound 17 (3,9-dihydroxy-dibenzo[b,d]pyran-6-one) with a content of 1 mg. Shirataki

307 and Toda have reported the isolation of 3,9-dihydroxy-dibenzo[b,d]pyran-6-one from *Trapa*
308 *natans* fruits, and it is believed to act as an antioxidant and inhibit lipid peroxidation.¹⁹ Its
309 structure was elucidated based on MS and various NMR spectroscopic data. Compound 17, the
310 molecular formula: C₁₃H₈O₄, positive ESI-MS *m/z*: 229.1 [M+H]⁺; ¹H NMR (700 MHz, CD₃OD)
311 δ 8.02 (d, *J* = 8.8 Hz, 1H, H-1), 6.81 (dd, *J* = 8.8, 2.3 Hz, 1H, H-2), 7.23 (d, *J* = 2.2 Hz, 1H, H-
312 4), 7.89 (d, *J* = 8.8 Hz, 1H, H-7), 6.80 (dd, *J* = 8.7, 2.4 Hz, 1H, H-8), 6.67 (d, *J* = 2.4 Hz, 1H, H-
313 10); ¹³C NMR (176 MHz, CD₃OD) δ 132.06 (C-1), 118.50 (C-2), 170.1 (C-3), 106.73 (C-4),
314 138.11 (C-5), 110.19 (C-6), 123.84 (C-7), 112.84 (C-8), 160.28 (C-9), 102.71 (C-10), 152.69
315 (C-11), 163.00 (C-13), 107.6 (C-14).

316

317 **Cell cycle analysis**

318 When cells were exposed to *t*-BHP, there was a distinct increase in the percentage of cells with
319 sub-G1 DNA content (12.66%), which was considered an indicator of cell damage (Table 3).
320 However, by pretreating cells with 5, 10, and 20 µg/mL EF, the percentage of cells in the sub-
321 G1 phase decreased to 7.41%, 7.27%, and 5.95%, respectively. These results indicate that the
322 EF protects cells from *t*-BHP-induced oxidative damage.

323

324 **Apoptosis analysis**

325 Apoptosis in Chang cells was tested by Annexin V/PI double staining. As shown in Figure 3A,
326 exposure to *t*-BHP (100 μ M) yielded a significant increase in Annexin V-positive cells (40.32%).
327 However, the EF pretreatment (5, 10, and 20 μ g/mL) significantly and dose-dependently
328 reduced the number of Annexin V-positive cells to 16.86% (5 μ g/mL), 14.52% (10 μ g/mL), and
329 9.29% (20 μ g/mL), respectively. These measurements indicate that the EF may protect against *t*-
330 BHP-induced injury by inhibiting apoptosis.

331

332 **Measurement of mitochondrial membrane potential (MMP)**

333 We investigated the effect of EF on the MMP in *t*-BHP-treated Chang cells. As shown in Figure
334 3B, the MMP of cells incubated with *t*-BHP decreased 23.75% compared to untreated cells,
335 indicating that *t*-BHP causes mitochondrial damage. However, the EF pretreatment significantly
336 protected Chang cells by increasing the mitochondrial membrane potential of *t*-BHP-treated
337 cells by 1.89% (5 μ g/mL), 1.68% (10 μ g/mL), 1.50% (20 μ g/mL), and 3.73% (silymarin, 5 mM).

338

339 **Intracellular ROS content**

340 To confirm that the EF reduced *t*-BHP-induced oxidative stress in Chang cells, intracellular
341 ROS production was assessed by monitoring DCFH-DA fluorescence. After *t*-BHP treatment,
342 intracellular oxidant levels increased, but cells pretreated with the EF exhibited reduced ROS
343 generation compared to *t*-BHP-stressed cells. After 24 h of 100 μ M of *t*-BHP treatment, 72.22%

344 of cells were DCFH-DA fluorescent, while 28.71% (5 µg/mL), 14.88% (10 µg/mL), and 3.72%
345 (20 µg/mL) of the EF pretreated cells were fluorescent. The positive control NAC (5 mM)
346 exhibited a 34.22% decrease in ROS content Figure (3C). These results indicate that ROS
347 production caused by *t*-BHP-induced oxidative damage reduces in a dose-dependent manner
348 when Chang cells are treated with the EF. The EF was a stronger inhibitor of ROS production
349 than NAC.

350

351 **Western blot analysis**

352 We hypothesized that the EF protects cells against *t*-BHP-induced oxidative stress by inhibiting
353 apoptosis. Hence, we attempted to investigate the potential molecular mechanisms involved. We
354 detected the expression of Bcl-2 (26 kDa), Bax (21 kDa), and the cleaved forms of caspase-3
355 (17,19 kDa), caspase-7 (18 kDa), caspase-8 (41, 43 kDa), and caspase-9 (37 kDa). We found
356 that pretreatment with the EF (5, 10, and 20 µg/mL) can dose-dependently inhibit caspase-7,
357 caspase-8, and caspase-9 protein expressions Figure (3D).

358

359 **Pathological histology estimation**

360 Treatment with *t*-BHP caused neutrophilic infiltration and cell death, which are the frequently
361 and widely observed salient features on the surface of the liver, including focal necrosis,

362 inflammatory cell infiltration, and massive histological changes (Figure 4). However,
363 microscopic examination showed that the severe hepatic lesions induced by *t*-BHP were
364 markedly reduced by the EF administration (50 mg/kg and 100 mg/kg).

365

366 **GOT and GPT assay**

367 We investigated the effect of EF on *t*-BHP-induced changes on the hepatic enzymes GOT and
368 GPT. GOT and GPT are well known biomarkers for early acute hepatic damage. The *t*-BHP (2
369 mmol/kg) treated group showed a 2.2-fold increase in mice serum GOT levels and a 14.2-fold
370 increase in GPT levels, whereas pretreatment with 50 and 100 mg/kg EF significantly
371 suppressed *t*-BHP-induced acute hepatotoxicity reactions (Table 4).

372

373 **Measurement of antioxidant activity of hepatic enzymes, lipid peroxidation, and total** 374 **antioxidant activity**

375 We investigated the activity of relevant antioxidant enzymes during *t*-BHP-induced oxidative
376 stress. *t*-BHP treatment significantly decreased CAT and SOD activity compared to the control
377 group (Table 4). The EF-treated group recovered their enzyme activity, and the silymarin group
378 displayed significantly enhanced enzyme activity compared to the control group.

379 GSH is known to play a protective role against *t*-BHP-induced toxicity. While *t*-BHP

380 administration significantly reduced GSH levels, pretreatment with the EF significantly
381 recovered GSH depletion by *t*-BHP. In terms of lipid peroxidation inhibition, we observed
382 significantly lower MDA levels in the EF-treated groups (50 mg/kg, 100 mg/kg) than the only *t*-
383 BHP treated group (Table 4). In addition, the group treated with 100 mg/kg silymarin had even
384 lower MDA levels than the untreated group. The scavenging activity of the EF on ABTS⁺
385 radicals generated by potassium persulfate was compared to a standard amount of Trolox. We
386 found that 50 mg/kg EF (TEAC value 0.356) and 100 mg/kg EF (TEAC value 0.372) displayed
387 a higher radical scavenging activity than the *t*-BHP-only treated group (TEAC value 0.337;
388 Table 4). These results reveal that the EF has strong antioxidant activity.

389

390 **Discussion**

391 In this study, three antioxidant assays (DPPH, ABTS, and FRAP) were determined to obtain
392 more precise evaluation of antioxidant activities of TJP extract and its various fractions. As
393 mentioned in earlier reports,²⁰ we also used a *t*-BHP-based model to induce oxidative stress and
394 subsequent cellular damage to investigate the protective effects of EF.

395 In this study, EF and BF were observed to have powerful antioxidant activities, comparable to
396 vitamin C. Also, we found EF has more strong protective effect against *t*-BHP-induced
397 oxidative stress in *in vitro* and *in vivo* studies. Interestingly, we also discovered a compound

398 known as 3,9-dihydroxy-dibenzo[b,d]pyran-6-one. This compound was also reported by
399 Shirataki and colleagues and was obtained from *Trapa natans* fruit. This is of interest since, 3,9-
400 dihydroxy-dibenzo[b,d]pyran-6-one is believed to act as an antioxidant and inhibit lipid
401 peroxidation.¹⁹

402 The EF increased cell survival, as measured by the cellular metabolic activity (MTT assay) and
403 plasma membrane integrity (LDH assay). We found that the EF protects against *t*-BHP-induced
404 oxidative stress by measuring oxidative stress markers, such as the intracellular accumulation of
405 ROS. In our results, the EF showed significant cytoprotective and antioxidant effects against *t*-
406 BHP-induced oxidative stress through the inhibition of ROS production and mitochondrial
407 damage. In many cases, ROS is an important component of cell death.²¹⁻²² Thus, we
408 hypothesized that the EF's protective effect might be mediated by inhibition of ROS-mediated
409 apoptosis. To assess this possibility in Chang cells, cell cycle analysis was performed by flow
410 cytometry. We found that *t*-BHP caused Chang cells to accumulate in sub-G1, but the EF
411 pretreatment dose-dependently reduced the sub-G1 population.

412 Various regulatory proteins such as the Bcl-2 family have been implicated in the induction of
413 the mitochondrial apoptotic signaling pathway.²³ We explored the signal pathway involved in
414 the EF's protective effect against *t*-BHP-induced oxidative stress in Chang cells. We found that
415 EF significantly reduced Bax and upregulated Bcl-2 in *t*-BHP-exposed Chang cells. In general,

416 apoptosis is regulated by an intrinsic mitochondria-mediated pathway and/or an extrinsic
417 receptor-mediated pathway.²⁴ Both pathways are mediated by the activation of caspases, which
418 are cysteine-aspartic proteases.²⁵ There are two types of apoptotic caspases, initiator caspases
419 and effector caspases.²⁶ Initiator caspases (e.g., caspase-2, caspase-8, caspase-9, and caspase-10)
420 cleave inactive pro-forms of effector caspases, thereby activating them.²⁷ Effector caspases (e.g.,
421 caspase-3, caspase-6, and caspase-7) in turn cleave other protein substrates within the cell to
422 trigger the apoptotic process.²⁸ The EF pretreatment effectively reduced these *t*-BHP-induced
423 intrinsic and extrinsic pro-apoptotic events. In our *in vivo* study, animals were pretreated with
424 the EF over a 5-day period before being exposed to *t*-BHP to investigate the protective potential
425 of the EF. Our results showed that *t*-BHP increased hepatic GOT, GPT, and MDA levels;
426 however, pretreatment with the EF effectively decreased these phenomena. As measured by
427 TBARS, the EF displayed significantly great inhibitory activity on lipid peroxidation. In
428 addition, pretreatment with the EF (50 and 100 mg/kg) conferred significant protection against
429 *t*-BHP-induced oxidative stress in male ICR mice. Based on histopathological analysis, the EF
430 treatment showed normal morphology compared to the control group. Therefore, we consider
431 the EF to be a good candidate material for the prevention or treatment of liver dysfunction.

432

433 **Conclusion**

434 We demonstrated that the EF increased cell viability by reducing the intracellular accumulation
435 of ROS, which contributes to apoptosis, in Chang cells. The mechanism for the EF's protective
436 and preventive effects is most likely mediated by the inhibition of apoptosis through the
437 regulation of caspase signaling pathways. Mice pretreated with the EF exhibited
438 hepatoprotective effects against liver damage caused by *t*-BHP-induced oxidative stress.
439 Therefore, EF could be used as a source of natural antioxidants and may have potential
440 application as a food supplement.

441

442 **Conflict of Interest**

443 The authors declare that there are no conflicts of interest.

444

445 **Acknowledgements**

446 This work was supported by a special grant from Konkuk University in 2016.

447

448 **References**

- 449 1. H. Sies, *Exp. Physiol.* 1997, **82**, 291-295.
- 450 2. P. Sharma, A. B. Jha, R. S. Dubey and M. Pessarakli, *J. Botany.* 2012, **26**, 1-26.
- 451 3. Y. Gilgun-Sherki, E. Melamed and D. Offen, *Neuropharmacol.* 2001, **40**, 959-975.
- 452 4. M. Valko, D. Leibfritz, J. Moncol, M. T. Cronin, M. Mazur and J. Telser, *Int. J. Biochem. Cell*
453 *Biol.* 2007, **39**, 44-84.
- 454 5. B. Halliwell and C. E. Cross, *Env. Health Persp.* 1994, **102**, 5-12.
- 455 6. R. I. Salganik, *J. Am. College Nutr.* 2001, **20**, 464S-472S.
- 456 7. S. A. Gautham and R. Onkarappa, *Int. J. Drug Dev. Res.* 2013, **5**, 235-244.
- 457 8. S. H. Wang, M. Y. Kao, S. C. Wu, D. Y. Lo, J. Y. Wu, J. C. Chang and R. Y. Chiou, *J. Agr:*
458 *Food Chem.* 2011, **59**, 3686-3692.
- 459 9. K. Shindo, E. Kuroki and M. Toyoda, *J. home economics. Japan.* 2013, **64**, 353-359.
- 460 10. M. Yasuda, K. Yasutake, M. Hino, H. Ohwatari, N. Ohmagari, K. Takedomi, T. Tanaka and
461 G. Nonaka, *Food Chem.* 2014, **165**, 42-49.
- 462 11. D. T. Ha, J. Oh, N. M. Khoi, T. T. Dao, V. Dung le, T. N. Do, S. M. Lee, T. S. Jang, G. S.
463 Jeong and M. K. Na, *J. Ethnopharmacol.* 2013, **150**, 875-885.
- 464 12. M. K. Kim, H. S. Lee, E. J. Kim, N. H. Won, Y. M. Chi, B. C. Kim and K. W. Lee, *Food*
465 *Chem Toxicol.* 2007, **45**, 1738-1744.

- 466 13. E. K. Kim, S. J. Lee, B. O. Lim, Y. J. Jeon, M. D. Song, T. K. Park, K. H. Lee, B. Kim, S. R.
467 Lee, S. H. Moon, B. T. Jeon and P. J. Park, *Food Sci. Biotechnol.* 2008, **17**, 279-286.
- 468 14. N. Erkan, G. Ayranci and E. Ayranci, *Food Chem.* 2008, **110**, 76-82.
- 469 15. I. F. Benzie and J.J. Strain, *Anal. Biochem.* 1996, **239**, 70-76.
- 470 16. M. Senevirathne, C. B. Ahn and J. Y. Je, *Carbohydrate Polym.* 2011, **83**, 995-1000.
- 471 17. H. Jin, T. Liu, W. X. Wang, J. H. Xu, P. B. Yang, H. X. Lu, Q. R. Sun and H. T. Hu,
472 *Neurochem Int.* 2010, **56**, 417-423.
- 473 18. J. Fernández, J. A. Pérez-Álvarez and J. A. Fernández-López, *Food Chem.* 1997, **59**, 345-
474 353.
- 475 19. Y. Shirataki and S. Toda, *Nature Med.* 2001, **55**, 247-250.
- 476 20. C. O. Hong, C. H. Rhee, N. H. Won, H. D. Choi and K. W. Lee, *Food Chem Toxicol.* 2013,
477 **53**, 214-220.
- 478 21. J. L. Franklin, *Antioxid. Redox Sign.* 2011, **14**, 1437-1448.
- 479 22. D. C. Wallace, *Genes Dev.* 2010, **24**, 1571-1573.
- 480 23. O. H. You, S. H. Kim, B. Kim, E. J. Sohn, H. J. Lee, B. S. Shim, M. Yun, B. M. Kwon and S.
481 H. Kim, *Bioorg. Med. Chem. Lett.* 2013, **23**, 2692-2695.
- 482 24. M. O. Hengartner, *Nature.* 2000, **407**, 770-776.
- 483 25. E. A. Slee, C. Adrain and S. J. Martin, *Cell Death & Differentiation.* 1999, **6**, 1067-1074.

484 26. S. Fulda, *Int. J. Cell Biol.* **2010**, 370835.

485 27. M. J. McManus, M. P. Murphy and J. L. Franklin, *Mol. Cell. Neurosci.* 2014, **63**, 13-23.

486 28. D. Acehan, X. Jiang, D. G. Morgan, J. E. Heuser, X. Wang and C. W. Akey, *Mol. Cell.* 2002,

487 **9**, 423-432.

488

489

490 **Figure captions**

491 **Figure 1. Chromatogram of the ethyl acetate fraction (EF) from the *Trapa japonica***
492 **pericarp obtained by an HPLC-PDA total scan.** Numbers correspond to the main compounds
493 detected and the isolated compounds (17) are reported.

494

495 **Figure 2. Effects of the ethanolic extract from *Trapa japonica* pericarp and its fractions**
496 **(hexane, chloroform, ethyl acetate, *n*-butanol and aqueous) in Chang cells.** (A) Cell
497 viability of the ethanolic extract from *Trapa japonica* pericarp and its fractions were measured
498 in Chang cells. (B) The protective effects of the ethyl acetate fraction (EF) were determined by
499 the mitochondrial tetrazolium (MTT) assay. (C) The LDH activity was measured as the LDH
500 release from damaged membranes, as described in Section 2. Data are represented as mean \pm
501 SD and were analyzed using a one-way ANOVA followed by the Dunnett's test. $###p < 0.001$
502 versus control, $***p < 0.001$ versus *tert*-butylhydroperoxide.

503

504 **Figure 3. Ethyl acetate fraction (EF) completely protects against *tert*-butylhydroperoxide**
505 **(*t*-BHP)-treated cells.** (A) Annexin V⁺/PI⁺ staining. Dot plots represent three independent
506 experiments with similar results. (B) Mitochondrial membrane potential (MMP) measurement.
507 (C) Intracellular reactive oxygen species (ROS) measurement. Values are expressed as the mean

508 \pm SD of three independent experiments. (D) Effect of the ethyl acetate fraction (EF) on the
509 expression of various caspases in the apoptotic pathway in Chang cells. Western blot analysis
510 for protein expression was represented for three independent experiments.

511

512 **Figure 4. Effect of the ethyl acetate fraction (EF) on *tert*-butylhydroperoxide (*t*-BHP)-**
513 **induced liver damage.** Mice were pretreated with EF and silymarin once daily for five
514 consecutive days. After the final treatment, mice were treated with *t*-BHP (2 mmol/kg, i.p.). (A,
515 a) Control group ($n = 5$), (B, b) animals treated with *t*-BHP showed spotty liver cell death with
516 neutrophilic infiltrates, (C, c) animals pretreated with 50 mg/kg EF and then *t*-BHP, (D, d)
517 animals pretreated with 100 mg/kg EF and then *t*-BHP, (E, e) and animals pretreated with 100
518 mg/kg silymarin and then *t*-BHP. Hematoxylin & eosin staining; magnification 200 \times .

519

520

521

522 **Table 1. Characterization of compounds in EF by LC-MS**

Peak	R_t (min)	λ_{\max} (nm)	[M- H] ⁻	Fragment (% intensity)	Assignment	Reference
1	2.39	215, 272	169	125 (100%), 91 (13%)	Gallic acid	Shindo <i>et al.</i> (2013)
2	2.82	211, 277	483	113 (9%), 91 (100%)	Digalloyl-glucoside	Shindo <i>et al.</i> (2013)
3	3.02	209, 278	483	91 (100%)	Digalloyl-glucoside	Shindo <i>et al.</i> (2013)
4	3.34	214, 276	483	113 (7%), 91 (100%)	Digalloyl-glucoside	Shindo <i>et al.</i> (2013)
5	3.65	208, 274	483	113 (7%), 91 (100%)	Digalloyl-glucoside	Shindo <i>et al.</i> (2013)
6	4.01	215, 276	483	113 (6%), 91 (100%)	Digalloyl-glucoside	Shindo <i>et al.</i> (2013)
7	4.37	216, 280	635	321 (13%), 91 (100%)	Trigalloyl-glucoside	Shindo <i>et al.</i> (2013)
8	4.90	215, 277	635	91 (100%)	Trigalloyl-glucoside	Shindo <i>et al.</i> (2013)
9	5.01	216, 275	635	392 (12%), 91 (100%)	Trigalloyl-glucoside	Shindo <i>et al.</i> (2013)
10	5.19	222, 278	635	465 (21%), 317 (17%), 240 (18%), 91 (100%)	Trigalloyl-glucoside	Shindo <i>et al.</i> (2013)
11	5.43	218, 277	635	317 (11%), 91 (100%)	Trigalloyl-glucoside	Shindo <i>et al.</i> (2013)
12	5.59	216, 277	635	91 (100%)	Trigalloyl-glucoside	Shindo <i>et al.</i> (2013)
13	5.86	216, 278	635	393 (31%), 317 (13%), 91 (100%)	Trigalloyl-glucoside	Shindo <i>et al.</i> (2013)
14	6.28	219, 277	937	787 (16%), 491 (16%), 479 (12%), 469 (10%), 468 (100%), 91 (30%)	Eugenin	Shindo <i>et al.</i> (2013) Yasuda <i>et al.</i> (2014)
15	6.52	224, 230, 273, 298	787	393 (57%), 91 (100%)	Tetrahalloyl- glucoside	Shindo <i>et al.</i> (2013) Yasuda <i>et al.</i> (2014)
16	6.94	254, 366	301	113 (6%), 91 (100%)	Ellagic acid	Wang <i>et al.</i> (2011)

523

524

525 **Table 2. DPPH radical scavenging activity, values for ABTS radical scavenging and FRAP**
 526 **of ethanolic extract from *Trapa japonica* pericarp and its fractions (hexane, chloroform,**
 527 **ethyl acetate, *n*-butanol and aqueous)**

Sample	DPPH radical scavenging activity (IC ₅₀ , µg/mL) ^a	TEAC (mM Trolox eq./mg extract) ^a	FRAP (mM FeSO ₄ eq./mg extract) ^a
EE	1.69 ± 0.01	1.521 ± 0.001	6.439 ± 0.200
HF	3.62 ± 0.02	1.268 ± 0.002	2.419 ± 0.089
CF	25.85 ± 0.25	1.053 ± 0.080	2.086 ± 0.023
EF	1.21 ± 0.01	1.523 ± 0.001	6.465 ± 0.173
BF	1.07 ± 0.01	1.525 ± 0.002	6.512 ± 0.207
AF	3.28 ± 0.21	1.519 ± 0.001	5.480 ± 0.115
Vitamin C	3.11 ± 0.20	1.528 ± 0.001	6.779 ± 0.191

528 TEAC (Trolox equivalent antioxidant capacity), FRAP (ferric reducing antioxidant power).

529 ^a Values represent means ± SD (*n* = 3).

530

531 **Table 3. Cell cycle analysis (%)**

Group	Sub-G1 phase	G1 phase	S phase	G2/M phase
Control	3.35 ± 0.21	43.71 ± 3.12	7.83 ± 1.26	34.86 ± 2.36
<i>t</i> -BHP (100 µM)	12.66 ± 2.23 ^{###}	25.71 ± 2.28	13.43 ± 2.13	38.90 ± 2.52
<i>t</i> -BHP + EF (5 µg/mL)	7.41 ± 1.01 ^{***}	24.57 ± 2.13	8.65 ± 1.25	50.02 ± 4.21
<i>t</i> -BHP + EF (10 µg/mL)	7.27 ± 1.25 ^{***}	27.5 ± 2.26	8.67 ± 2.32	44.36 ± 2.36
<i>t</i> -BHP + EF (20 µg/mL)	5.95 ± 0.78 ^{***}	42.73 ± 3.26	12.68 ± 2.14	31.29 ± 2.54
<i>t</i> -BHP + silymarin (50 µg/mL)	6.37 ± 1.05 ^{***}	23.37 ± 2.52	16.34 ± 2.42	47.85 ± 2.58

532 ^{###}*p* < 0.001 versus control, ^{***}*p* < 0.001 versus *tert*-butylhydroperoxide (*t*-BHP).

Table 4. Measurement of serum GOT, GPT, antioxidant activity of hepatic enzymes, lipid peroxidation and antioxidant activity

Group	GOT ^a	GPT ^b	SOD ^c	CAT ^d	Total GSH ^e	TBARS value ^f	TEAC ^g
Group I	36.75 ± 7.07	3.28 ± 1.07	26.08 ± 1.51	59.68 ± 8.46	21.69 ± 3.75	69.45 ± 15.64	0.368 ± 0.054
Group II	82.97 ± 3.39 [#]	46.61 ± 4.53 [#]	24.70 ± 2.09	42.10 ± 8.57 [#]	17.65 ± 2.01 [#]	97.52 ± 28.74 [#]	0.337 ± 0.020 [#]
Group III	74.53 ± 4.46 [*]	40.50 ± 3.16 [*]	25.56 ± 1.28	57.36 ± 5.52 [*]	18.95 ± 3.13	80.05 ± 19.54 [*]	0.356 ± 0.032 [*]
Group IV	65.53 ± 3.54 [*]	37.01 ± 5.20 [*]	26.35 ± 1.71	57.64 ± 7.44 [*]	19.82 ± 2.77 [*]	75.22 ± 30.40 [*]	0.372 ± 0.047 [*]
Group V	64.64 ± 4.05 [*]	34.07 ± 3.31 [*]	26.73 ± 0.98	52.79 ± 9.49 [*]	18.33 ± 1.38	65.63 ± 11.87 [*]	0.355 ± 0.033 [*]

Group I: Control group, Group II: animals treated with *tert*-butylhydroperoxide (*t*-BHP), Group III: animals pretreated with 50 mg/kg the ethyl acetate fraction (EF) and then *t*-BHP, Group IV: animals pretreated with 100 mg/kg EF and then *t*-BHP, Group V: animals pretreated with 100 mg/kg silymarin, and then *t*-BHP. ^aGlutamate oxaloacetate transaminase (GOT) levels were expressed as IU/L. ^bGlutamate pyruvate transaminase (GPT) levels were expressed as IU/L. ^cSuperoxide dismutase activities were expressed as U/mL. ^dCatalase activities were expressed as nmol/min/mL. ^eTotal glutathione levels were expressed as μM/mg protein. ^fMalondialdehyde levels were expressed as nmol/mg protein. ^gTrolox equivalent antioxidant capacities were expressed as mM Trolox equivalent/mg protein. Data are represented as mean ± SD (*n*=5) and were analyzed using a one-way ANOVA followed by the Dunnett's test. [#]*p* < 0.05 versus control, ^{*}*p* < 0.05 versus *t*-BHP.




Figure 1. Kim et al




Figure 2(A). Kim et al.




Figure 2(B). Kim et al.




Figure 2(C). Kim et al.




Figure 3(A). Kim et al.




Figure 3(B). Kim et al.




Figure 3(C). Kim et al.




Figure 3(D). Kim et al.





Figure 4. Kim et al.



214x104mm (150 x 150 DPI)